Skip to content

Unilever Global Change location

Unilever research identifies mouthwash technology with potential to reduce viral load of SARS-CoV-2 virus by 99.9%

Illustration of scientist looking through microscope

While we are clear that this is not a cure or proven way to prevent the transmission of coronavirus, the results are very promising, and given the critical stage of the pandemic we feel it is important to share them so that people are aware of the potential benefits of CPC containing mouthwashes alongside other preventative measures.

Glyn Roberts PhD, Head of Unilever Oral Care Research and Development

Unilever has confirmed that preliminary lab test results1 show that a mouthwash formulation containing CPC Technology, reduces 99.9%2 of SARS-CoV-2, the virus that causes COVID-19, after 30 seconds of rinsing.

The preliminary test results on SARS-CoV-2 build on existing Unilever research published on the biology research platform bioRxiv, and follow ongoing discussions in the global medical and scientific community around the potential use of mouthwash as an additional measure to reduce the transmission of the virus. Research into the duration of the effect continues, but a previous study3 on a small group of patients infected with COVID-19 suggest that viral load – the amount of virus particles a person is carrying - may be reduced in the mouth for up to six hours by using mouthwashes containing CPC.

These preliminary test results, showing the efficacy of CPC Technology against the SARS-CoV-2 virus, are the latest in a large range of studies that are evaluating the efficacy of mouthwash technology against a number of viruses. In the tests we have done, only CPC Technology has to date shown positive results consistently.

Illustration of Virus that causes Covid-19

The virus that causes COVID-19 spreads primarily through droplets of saliva or discharge from the nose, which has been detected before, during, and after the acute phase of illness, as well as in asymptomatic cases4. Therefore, reducing the viral load in the mouth could help to reduce transmission. The findings indicate that mouthwash could become an important addition to other protective measures like handwashing, physical distancing and mask wearing.

Image of mouthwash with CPC Technology

Glyn Roberts PhD, Head of Unilever Oral Care R&D, says, “The results of the study are a promising step on our journey to understanding how mouthwashes could help reduce the spread of coronavirus5, alongside other preventative measures. Although our research is ongoing, we are sharing the results now so people can consider introducing a CPC-based mouthwash into their daily routine.

“We are committed to making CPC-based products available in as many countries as possible in the coming months6. Mouthwash products from other companies containing CPC could also have a positive effect, and we are sharing the findings in the spirit of openness and collaboration. We encourage others to continue research into the role that oral care products may have as an additional preventative measure during the pandemic.”

Eminent scientists have reviewed the Unilever research data and agree that it is in the public interest to share the results widely.

Professor Iain Chapple, Head of Research for Institute of Clinical Sciences, University of Birmingham, UK says, “Given its long history of safe use, and wide availability across the world, using a mouthwash that contains CPC Technology could offer a simple, effective, and safe step for people to take alongside existing COVID-19 protection and prevention measures as recommended by their health authorities. The results are promising and warrant further exploration with in vitro and human clinical studies. These are important to understand the substantivity of the anti-viral effect, in other words how long it lasts for in vivo. People should also continue to take all other existing precautions against the spread of the virus, including physical distancing, hand and surface hygiene, and face coverings.”

Dr Angela Rasmussen, PhD, Associate Research Scientist at the Center of Infection and Immunity at the Columbia University School of Public Health, adds, “While research has previously been published into the effect of mouthwashes against surrogate coronaviruses, this is the first study in a laboratory to demonstrate that mouthwashes containing CPC can be effective against the actual virus responsible for Covid-19, and that they do indeed lower the viral load in recognised tests of mouthwash use. Other research on the duration of effect of CPC in a mouthwash on bacteria and coronavirus would suggest that the reduction in infectious viral load is likely to be sustained over time. This effect has also been demonstrated on a small sample of COVID-19 patients.”

Media Contacts

Notes to editors

What is CPC? Cetylpyridinium chloride is a widely used cosmetic ingredient, also used by the dental industry, and is known for its antibacterial and anti-virus benefits.

How was the testing carried out? The tests were carried out by independent laboratories in the United States. We tested for both 30 and 60 seconds, rinse times, aiming to replicate the real-life use of mouthwash in an in-vitro context.

What do the results show? The preliminary results show a mouthwash formulation containing CPC (cetylpyridinium chloride) is effective in reducing the viral load by 99.9% after 30 seconds of rinsing, which is consistent with typical usage of mouthwash. The tests do not suggest that the formulation is a treatment for COVID-19, nor a guarantee that it will prevent transmission on its own. Established protective measures advised by health authorities should be followed, including hand washing, physical distancing and wearing masks.

What about alcohol in mouthwash? Mouthwashes that contain alcohol (ethanol) typically contain it at 11-14%. Data suggests at this concentration and time relevant to mouthwash use, ethanol is unlikely to be effective against viruses.

Safe Harbour

Where relevant, these actions are subject to the appropriate consultations and approvals.

This announcement may contain forward-looking statements, including ‘forward-looking statements’ within the meaning of the United States Private Securities Litigation Reform Act of 1995. Words such as ‘will’, ‘aim’, ‘expects’, ‘anticipates’, ‘intends’, ‘looks’, ‘believes’, ‘vision’, or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Unilever Group (the ‘Group’). They are not historical facts, nor are they guarantees of future performance.

Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: Unilever’s global brands not meeting consumer preferences; Unilever’s ability to innovate and remain competitive; Unilever’s investment choices in its portfolio management; the effect of climate change on Unilever’s business; Unilever’s ability to find sustainable solutions to its plastic packaging; significant changes or deterioration in customer relationships; the recruitment and retention of talented employees; disruptions in our supply chain and distribution; increases or volatility in the cost of raw materials and commodities; the production of safe and high quality products; secure and reliable IT infrastructure; execution of acquisitions, divestitures and business transformation projects; economic, social and political risks and natural disasters; financial risks; failure to meet high and ethical standards; and managing regulatory, tax and legal matters. A number of these risks have increased as a result of the current Covid-19 pandemic.

These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Further details of potential risks and uncertainties affecting the Group are described in the Group’s filings with the London Stock Exchange, Euronext Amsterdam and the US Securities and Exchange Commission, including in the Unilever Annual Report and Accounts 2020.


In vitro test which attempts to simulate viral load in the mouth


Results subject to final audit


Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore (non-Unilever research)


WHO: and L.L. Fernandes et al., Journal of Dental Research, 1–9


All references to coronavirus refer to ‘SARS-CoV-2’, the virus strain responsible for Covid-19


Excluding North America